Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Imatinib Stories

2009-06-08 07:27:59

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.Jackson Adjunct Professor Shaoguang Li, M.D., Ph.D., who now has a laboratory at the University of Massachusetts Medical School in Worcester, led a research team that identified a gene involved with the inflammatory response that could hold the key to...

2009-06-07 12:36:18

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market. Jackson Adjunct Professor Shaoguang Li, M.D., Ph.D., who now has a laboratory at the University of Massachusetts Medical School in Worcester, led a research team that identified a gene involved with the inflammatory response that could hold the key to...

2009-05-28 08:30:00

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL. Quest Diagnostics Incorporated (NYSE: DGX) is the world's leading provider of diagnostic testing, information and...

2009-05-28 00:28:00

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of Glivec(R)...

2009-05-15 09:34:27

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.Lori Rink, PhD, a postdoctoral fellow in the laboratory of Andrew K. Godwin, PhD, at Fox Chase, presents their findings at the 2009 Annual Meeting of the American...

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been...

2009-04-15 11:07:33

U.S. and British scientists say they've identified a class of drugs that may enhance the effectiveness of medications used to treat chronic myeloid leukemia. People with chronic myeloid leukemia are usually first treated with a drug known as imatinib mesylate. Although very effective at first, the body often becomes resistant to the drug as the disease progresses. Now a team of researchers from Britain's University of Leicester and Thomas Jefferson University in Philadelphia has identified a...

2009-03-18 17:37:00

- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs. 83% for patients taking placebo(1) - Historically, one in two patients experienced recurrence of GIST(2) within a median of two years after surgery(3) - Gleevec is the only treatment in the US and Switzerland indicated to reduce risk of recurrence of GIST after surgery; regulatory review is underway in the EU(4) EAST HANOVER, N.J., March 18, 2009 /PRNewswire/ -- Data published today...

2009-01-16 13:45:22

Scientists from the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation have found a specific mutation that leads to the development of severe autoimmune kidney disease in mice. The research sheds light on the basic biology of the immune system, as well as on the effectiveness of drugs such as the anti-leukemia medication Gleevec/Imatinib.The study was published in the January 16, 2009 edition (Volume 33, No. 1) of the journal Molecular Cell.In the study,...

2008-12-19 18:41:00

Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec. 19 /PRNewswire/ -- Novartis announced today...